Study of XL999 in Patients With Acute Myeloid Leukemia (AML)

Summary

This clinical study is being conducted at multiple sites to determine the activity, safety and tolerability of XL999 when given weekly to patients with relapsed or newly-diagnosed AML. XL999 is a small molecule inhibitor against Flk1/kinase insert domain receptor (KDR), PDGFR, c-Kit, FLT3 and SRC. c-Kit and FLT3 are receptors commonly expressed on AML blasts.

Timeline

Start

2006-05

Primary completion

2006-11

Completion

2007-05

Outcome

Outcome not reported

Stopped: “Study was terminated due to cardiac toxicities”

Drugs

Indications